HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| (12 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
Welcome! | Ian Welcome! | ||
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | '''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | ||
| Line 1,403: | Line 1,403: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | ||
|Disease | |Disease | ||
| | |To be covered in B-ALL, NOS | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,422: | Line 1,422: | ||
| | | | ||
| | | | ||
| | |Complete (pending review by SK) | ||
| | | | ||
|SK | |SK | ||
| Line 1,438: | Line 1,438: | ||
| | | | ||
| | | | ||
| | |Complete (pending review by SK) | ||
| | | | ||
|SK | |SK | ||
| Line 1,469: | Line 1,469: | ||
|Karin Miller, MD | |Karin Miller, MD | ||
|10/9/2025 | |10/9/2025 | ||
| | |12/5/2025 | ||
| | | | ||
| | | | ||
| Line 1,583: | Line 1,583: | ||
|10/10/2025 | |10/10/2025 | ||
|11/24/2025 | |11/24/2025 | ||
|Complete (pending SK review) | |||
|11/11/2025 | |||
|SK | |||
|Pending | |Pending | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,611: | Line 1,611: | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | ||
|Disease | |Disease | ||
|Karin Miller, MD | |||
|10/9/2025 | |||
|11/24/2025 | |||
|Pending | |||
| | | | ||
|SK | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
!Disease (5th Edition) | !Disease (5th Edition) | ||
| Line 2,500: | Line 2,487: | ||
|Disease | |Disease | ||
|Parastou Tizro, MD; | |Parastou Tizro, MD; | ||
Celeste Eno, PhD | Celeste Eno, PhD; Sumire Kitahara, MD | ||
|9/23/2025 | |9/23/2025 | ||
|11/4/2025 | |11/4/2025 | ||
| Line 2,530: | Line 2,517: | ||
|9/24/2025 | |9/24/2025 | ||
|12/9/2025 | |12/9/2025 | ||
| | |'''Complete''' | ||
| ||SK|| || | | 12/17/2025||SK|| 1/6/2026|| | ||
|Chronic Lymphoproliferative Disorder of NK Cells | |Chronic Lymphoproliferative Disorder of NK Cells | ||
|Michelle Don, MD | |Michelle Don, MD | ||
| Line 2,585: | Line 2,572: | ||
!Prior Notes (4th Edition) | !Prior Notes (4th Edition) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease|| | |[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD | ||
| | |1/6/2026 | ||
| || | | 2/3/2026|| | ||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,600: | Line 2,587: | ||
|10/14/2025 | |10/14/2025 | ||
|11/24/2025 | |11/24/2025 | ||
| | |'''Complete''' | ||
| ||SK|| || | | 12/29/2025||SK|| 1/6/2026|| | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,640: | Line 2,627: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease|| | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD | ||
| | Katelyn Swanson, DO (trainee) | ||
| | |11/19/2025 | ||
| | |12/19/2025 | ||
| ||SK|| || | |'''Complete''' | ||
| 1/6/2026||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,667: | Line 2,655: | ||
Andrew Siref, MD | Andrew Siref, MD | ||
|10/14/2025||11/24/2025 | |10/14/2025||11/24/2025 | ||
| | |'''Complete''' | ||
| ||SK|| || | | 12/29/2025||SK|| 1/6/2026|| | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,745: | Line 2,733: | ||
|9/24/2025 | |9/24/2025 | ||
|11/9/2025 | |11/9/2025 | ||
| | |'''Complete''' | ||
| | |12/17/2025 | ||
|SK||1/6/2026|| | |||
|Hepatosplenic T-cell Lymphoma | |Hepatosplenic T-cell Lymphoma | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
| Line 2,850: | Line 2,839: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease|| | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD | ||
|1/6/2026 | |||
| | | 2/3/2026||Pending | ||
| ||Pending | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,877: | Line 2,865: | ||
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | |[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| ||Pending | | 11/17/2025||Pending | ||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,887: | Line 2,875: | ||
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| ||Pending | | 11/17/2025||Pending | ||
| ||SK|| ||prior authors not available | | ||SK|| ||prior authors not available | ||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |Systemic EBV-Positive T-cell Lymphoma of Childhood | ||